Free Trial

Kodiak Sciences (KOD) Competitors

Kodiak Sciences logo
$12.48 +0.88 (+7.59%)
Closing price 10/14/2025 04:00 PM Eastern
Extended Trading
$12.32 -0.16 (-1.31%)
As of 10/14/2025 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KOD vs. CNTA, XENE, CGON, QURE, RARE, APLS, IMVT, GMTX, OGN, and MOR

Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), uniQure (QURE), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Gemini Therapeutics (GMTX), Organon & Co. (OGN), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.

Kodiak Sciences vs. Its Competitors

Kodiak Sciences (NASDAQ:KOD) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Kodiak Sciences had 5 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 10 mentions for Kodiak Sciences and 5 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.70 beat Kodiak Sciences' score of 0.63 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kodiak Sciences
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Centessa Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Centessa Pharmaceuticals' return on equity of -40.39% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -155.27% -63.29%
Centessa Pharmaceuticals N/A -40.39%-29.87%

Kodiak Sciences has a beta of 2.67, meaning that its stock price is 167% more volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Kodiak Sciences presently has a consensus price target of $13.20, indicating a potential upside of 5.77%. Centessa Pharmaceuticals has a consensus price target of $32.38, indicating a potential upside of 44.47%. Given Centessa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Centessa Pharmaceuticals is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Centessa Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by insiders. Comparatively, 7.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kodiak Sciences has higher earnings, but lower revenue than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$176.21M-$3.80-3.28
Centessa Pharmaceuticals$6.85M438.09-$235.76M-$1.79-12.52

Summary

Centessa Pharmaceuticals beats Kodiak Sciences on 9 of the 15 factors compared between the two stocks.

Get Kodiak Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KOD vs. The Competition

MetricKodiak SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$612.73M$3.36B$6.05B$10.52B
Dividend YieldN/A2.31%5.73%4.79%
P/E Ratio-3.2821.9085.0527.24
Price / SalesN/A476.87595.29234.24
Price / CashN/A46.9537.5761.53
Price / Book4.3610.4312.676.74
Net Income-$176.21M-$52.58M$3.32B$276.59M
7 Day Performance-13.69%-1.55%-1.34%-0.47%
1 Month Performance33.48%12.96%8.11%7.47%
1 Year Performance333.33%15.43%78.90%34.58%

Kodiak Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KOD
Kodiak Sciences
3.3498 of 5 stars
$12.48
+7.6%
$13.20
+5.8%
+331.8%$612.73MN/A-3.2890Gap Up
CNTA
Centessa Pharmaceuticals
2.8361 of 5 stars
$23.00
-1.0%
$32.38
+40.8%
+34.5%$3.11B$6.85M-12.85200Analyst Upgrade
XENE
Xenon Pharmaceuticals
2.4786 of 5 stars
$39.55
-0.2%
$53.30
+34.8%
-2.8%$3.05B$9.43M-11.14210Analyst Forecast
CGON
CG Oncology
2.1819 of 5 stars
$38.13
-4.2%
$56.55
+48.3%
+14.2%$3.04B$1.14M-21.5461
QURE
uniQure
3.5578 of 5 stars
$52.91
-3.7%
$71.75
+35.6%
+945.4%$3.01B$27.12M-13.50500
RARE
Ultragenyx Pharmaceutical
4.2823 of 5 stars
$30.19
-3.3%
$81.50
+170.0%
-43.6%$3.01B$610.16M-5.461,294Insider Trade
APLS
Apellis Pharmaceuticals
4.188 of 5 stars
$24.36
+2.4%
$33.29
+36.7%
-15.4%$3.01B$781.37M-13.38770
IMVT
Immunovant
2.1292 of 5 stars
$16.55
-2.1%
$33.20
+100.6%
-40.6%$2.95BN/A-5.81120News Coverage
Analyst Forecast
Gap Down
GMTX
Gemini Therapeutics
N/A$67.78
+2.9%
N/A+50.7%$2.94BN/A-67.7830
OGN
Organon & Co.
4.8089 of 5 stars
$10.84
-1.5%
$17.33
+59.9%
-47.1%$2.86B$6.40B4.034,000
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730

Related Companies and Tools


This page (NASDAQ:KOD) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners